Skip to content
sugarisadrug.com
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

Author: sugaradmin

2159-LB: Hepatic PAQR4 Contributes to Metabolic Regulation by Mediating Ceramide Levels and Hepatokine Signaling

July 13, 2025 by sugaradmin

Introduction and Objective: PAQR4, an orphan receptor within the progestin and adipoQ receptor family (PAQR1-11), is implicated in multiple cancers, including hepatocellular carcinoma (HCC). However, its metabolic function in hepatocytes remains unclear. Our recent findings identify PAQR4 as a key regulator of ceramide metabolism. In adipocytes, PAQR4 overactivation leads to ceramide accumulation, disrupting adipose tissue […]

Read More
DiabetesLeave a Comment on 2159-LB: Hepatic PAQR4 Contributes to Metabolic Regulation by Mediating Ceramide Levels and Hepatokine Signaling

1006-P: Developing CGMap—Characterizing Continuous Glucose Monitoring Data in Patients with Type 2 Diabetes

July 12, 2025 by sugaradmin

Introduction and Objective: To characterize continuous glucose monitoring (CGM) data in patients with type 2 diabetes (T2D), and to assess the relationship between CGM-derived indicators and diabetes-related clinical parameters.Methods: The data was collected from a randomized trial in China (ChiCTR2000039424), in which patients with T2D wore CGM and received acarbose or sitagliptin. Ordinary least square […]

Read More
DiabetesLeave a Comment on 1006-P: Developing CGMap—Characterizing Continuous Glucose Monitoring Data in Patients with Type 2 Diabetes

2158-LB: Additive Hepatoprotective Effects of DA-1241, a GPR119 Agonist, in Combination with Efruxifermin in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH

July 12, 2025 by sugaradmin

Introduction and Objective: DA-1241, a novel G protein-coupled receptor 119 agonist, recently completed a Phase 2a clinical trial in presumed metabolic dysfunction-associated steatohepatitis (MASH) patients. This study extended previous findings on its hepatoprotective synergy with glucagon-like peptide-1-based drugs and evaluated its anti-MASH effects in combination with a fibroblast growth factor 21 analogue.Methods: Male C57BL/6JRj mice […]

Read More
DiabetesLeave a Comment on 2158-LB: Additive Hepatoprotective Effects of DA-1241, a GPR119 Agonist, in Combination with Efruxifermin in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH

22-OR: Type 2 Diabetes Subtypes and Risk of Dementia in the United States

July 12, 2025 by sugaradmin

Introduction and Objective: Dementia, an emerging complication of type 2 diabetes (T2D), may be driven by chronic hyperglycemia and insulin resistance. We evaluated the risk of dementia across T2D subtypes, which differ in clinical profiles and risk of vascular complications.Methods: We identified newly diagnosed T2D (n = 727,076; age: 64.4 years [SD:13.3], 52% female) over […]

Read More
DiabetesLeave a Comment on 22-OR: Type 2 Diabetes Subtypes and Risk of Dementia in the United States

2157-LB: The Metabolic Impact of Weight Cycling on Normal Weight Mice and Exploration of Its Mechanisms

July 12, 2025 by sugaradmin

Introduction and Objective: An increasing number of individuals with normal weight are attempting weight loss through caloric restriction. However, most weight loss attempts are followed by weight regain, leading to weight cycling. Whether weight cycling poses metabolic risks, especially in normal-weight individuals, remains debated. This study aims to evaluate the effects of weight cycling on […]

Read More
DiabetesLeave a Comment on 2157-LB: The Metabolic Impact of Weight Cycling on Normal Weight Mice and Exploration of Its Mechanisms

684-P: Community-Based Peer Support for Diabetes Management in Shanghai, China—Breadth of Benefits and Processes of Change

July 12, 2025 by sugaradmin

Introduction and Objective: Characterize breadth of benefits, relationships among changes, and processes of change in Community-Based Peer Support (CPS).Methods: CPS was implemented over 24 months in 12 communities (n=1,018) with 4 Comparison Communities (Comp, n=423) in Shanghai, China. CPS participants were = 59.9% female vs 53.5% among Comp, older (mean 66.64 vs 62.94 years), and […]

Read More
DiabetesLeave a Comment on 684-P: Community-Based Peer Support for Diabetes Management in Shanghai, China—Breadth of Benefits and Processes of Change

2156-LB: Superior Hepatoprotective Effects of OPK-88006, a Novel GLP-1/Glucagon Receptor Dual Agonist, to Semaglutide and Survodutide in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH

July 12, 2025 by sugaradmin

Introduction and Objective: The present study aimed to investigate the hepatoprotective effects of OPK-88006, a novel GLP-1/glucagon receptor agonist, in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH with liver fibrosis. The late-stage clinical candidates semaglutide and survodutide for the treatment of patients with MASH and liver fibrosis, were included for comparison.Methods: Male […]

Read More
DiabetesLeave a Comment on 2156-LB: Superior Hepatoprotective Effects of OPK-88006, a Novel GLP-1/Glucagon Receptor Dual Agonist, to Semaglutide and Survodutide in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH

284-OR: Physiologic Compensation to Metabolic Stress following Islet α-Cell Loss

July 12, 2025 by sugaradmin

Introduction and Objective: Islet endocrine cells rely on efficient prohormone synthesis and elimination of misfolded peptides for proper function. We recently found that endoplasmic reticulum-associated degradation (ERAD) and autophagy are essential protein quality control systems that maintain α cell identity, ER homeostasis, and glucagon (Gcg) production.Methods: To investigate whether ERAD and autophagy serve overlapping roles […]

Read More
DiabetesLeave a Comment on 284-OR: Physiologic Compensation to Metabolic Stress following Islet α-Cell Loss

2155-LB: Hepatic BHMT Integrates GIP/GLP-1 Signaling to Ameliorate Metabolic Dysfunction through Coordinated Regulation of Lipid Metabolism and Fibrogenesis

July 12, 2025 by sugaradmin

Introduction and Objective: Metabolic dysfunction-associated steatohepatitis (MASH), a critical stage in NAFLD progression, lacks effective treatments. While GIP/GLP-1R dual agonists (GIP/GLP-1RA) show therapeutic potential, their mechanisms remain unclear. Our preclinical study identified serum BHMT downregulation by GIP/GLP-1RA. This study investigates the BHMT-incretin relationship, its roles in MASH pathogenesis, and its potential as a therapeutic target […]

Read More
DiabetesLeave a Comment on 2155-LB: Hepatic BHMT Integrates GIP/GLP-1 Signaling to Ameliorate Metabolic Dysfunction through Coordinated Regulation of Lipid Metabolism and Fibrogenesis

1919-LB: The Role of Dietary Patterns and Diabetes in Modulating the Risk of Sarcopenia among Adults in Qatar

July 12, 2025 by sugaradmin

Introduction and Objective: Understanding the relationship between diabetes, sarcopenia, and lifestyle factors like diet and physical activity remains limited, particularly in the MENA region. While most research focuses on individual nutrients, a dietary pattern approach offers a more comprehensive perspective. This study examines the impact of dietary patterns and diabetes on sarcopenia risk among adults […]

Read More
DiabetesLeave a Comment on 1919-LB: The Role of Dietary Patterns and Diabetes in Modulating the Risk of Sarcopenia among Adults in Qatar

Posts navigation

Older posts
Newer posts

Recent Posts

  • New Food Pyramid: What It Recommends Eating
  • Heart Attack: Energy Drinks May Quadruple Risk in Adults Under 35
  • Stroke, Heart Disease: Salt Substitutes May Prevent Millions of Deaths
  • Type 2 Diabetes: 54% Young Adults Enter Remission with Diet, Exercise
  • GLP-1s May Help Lower Diabetes Risk More Effectively Than Metformin

Recent Comments

  • A WordPress Commenter on SUCROSE: “PURE” ENERGY AT A PRICE

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • November 2024
  • October 2024
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • May 2017

Categories

  • Celebrity Health
  • Diabetes
  • Food Choices
  • Fructose
  • General Sugar
  • Glucose
  • Health News
  • Insulin
  • Mental Health
  • Natural Unrefined Sugar
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Sucrose
  • Sugar Science

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

© 2026 Sugar is a DRUG | Sugar Addiction Awareness